PRJNA564917
Effect of Vistusertib alone of in combination with fulvestrant in human breast cancer PDX models of acquired endocrine resistance
Combined therapy of vistusertib with fulvestrant showed synergy in estrogen receptor positive PDX models of resistance to endocrine therapy and delayed tumour progression after cessation of therapy. To understand the transcriptional impact of vistusertib alone or in combination with fulvestrant in tumours modelling acquisition of endocrine therapy.